Two-dose daclizumab induction in pediatric renal transplantation

Amrish Jain, Rudolph P. Valentini, Scott A. Gruber, Miguel S. West, Tej K. Mattoo, Abubakr A. Imam

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


DCZ, an IL-2 receptor antagonist, has been widely used for induction therapy in pediatric and adult solid organ transplantation. Originally, it was recommended as a five-dose regimen; however, fewer doses may be efficacious and less costly for prevention of rejection. There is limited experience with the use of fewer doses in pediatric renal transplantation. We retrospectively reviewed the outcomes of 26 primary pediatric renal transplants performed at a single center between June 2004 and May 2007 receiving induction therapy with two-dose DCZ (1.5 mg-kg preoperatively and day seven post-transplant). Maintenance immunosuppression included tacrolimus, MMF, and prednisone in all patients. Forty-six percent were African American and 92% were deceased-donor transplants. After a mean follow-up of 17.8 ± 7.5 months, acute rejection was noted in 11.5% and graft survival was 92.3%. CMV infection occurred in 11.5%, but no case of BK nephropathy or post-transplant lymphoproliferative disorder was observed. Our preliminary results suggest that induction therapy with two-dose DCZ was convenient, economical, and effective in preventing rejection episodes without an increase in adverse events or hospital stay. Larger randomized clinical trials with longer duration of follow-up are needed to more fully validate the use of this regimen in pediatric renal transplantation.

Original languageEnglish
Pages (from-to)490-494
Number of pages5
JournalPediatric Transplantation
Issue number4
StatePublished - Jun 2009


  • Acute rejection
  • Daclizumab
  • Induction therapy
  • Pediatric renal transplantation


Dive into the research topics of 'Two-dose daclizumab induction in pediatric renal transplantation'. Together they form a unique fingerprint.

Cite this